Materias dentro de su búsqueda.
Mostrando 501 - 520 Resultados de 1,900 Para Buscar '"AstraZeneca"', tiempo de consulta: 1.29s Limitar resultados
  1. 501
    “…The effectiveness of reducing outcomes after the administration of three COVID-19 vaccines (BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and AZD1222 (Oxford-AstraZeneca)) were modelled with empirical parameters obtained from literatures. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Economic evaluation for mass vaccination against COVID-19
  2. 502
    “…While administration of millions of doses of the adenoviral vector vaccines (e.g., Oxford-AstraZeneca (ChAdOx1 nCoV-19) and Janssen/Johnson & Johnson (Ad26.COV2. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cerebral Coagulation Complications Following COVID-19 Adenoviral Vector Vaccines: A Systematic Review
  3. 503
    “…Seventeen patients received the COMIRNATY Pfizer-BioNTech vaccine, two the Moderna mRNA-1273 vaccine, one the ChAdOx1/nCoV-19-AstraZeneca/ Vaxzevria vaccine and one received the first dose with the ChAdOx1/nCoV-19-AstraZeneca/Vaxzevria vaccine and the second dose with the COMIRNATY Pfizer-BioNTech vaccine. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study
  4. 504
    “…We also conducted an analysis of vaccine brands (Pfizer, Moderna, AstraZeneca) approved in Japan. RESULTS: The daily number of tweets continued with accelerating growth after the start of large-scale vaccinations in Japan. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Public Opinion and Sentiment Before and at the Beginning of COVID-19 Vaccinations in Japan: Twitter Analysis
  5. 505
    “…RESULTS: Among the 13 patients with post-COVID-19 vaccination GBS (9 males; mean age, 64 year), 5 were vaccinated with Oxford-AstraZeneca, 7 with Pfizer-BioNTech, and one with Moderna. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case series
  6. 506
    “…This Signal Assessment Guide (SAGe) tool was developed by AstraZeneca and is used internally, both to assess safety signal strength and to inform causality decisions related to safety signals. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Structured Methodology to Assess Safety Signal Strength and Inform Causality Assessment
  7. 507
    “…RESULTS: Overall, 221 patients were diagnosed with immunization stress-related responses (stroke-like symptoms) following CoronaVac (Sinovac) or ChAdOx1 (AstraZeneca) vaccinations. Most patients (83.7%) were women. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Good recovery of immunization stress-related responses presenting as a cluster of stroke-like events following CoronaVac and ChAdOx1 vaccinations
  8. 508
    “…In addition, this formulation induced significantly higher neutralizing antibody titers against the three viral variants when compared with authorized Gam-COVID-Vac-rAd26/rAd5 (Sputnik V) or ChAdOx1 (AstraZeneca) vaccines. SW2-Vac 2µg was also able to induce IFN-gamma and IL-17, memory CD4 populations and follicular T cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern
  9. 509
    “…Even though the immune response to the Pfizer and Moderna vaccines were evaluated after a longer period than AstraZeneca, the immune response in residents vaccinated with these vaccines were superior. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immune Response After Vaccination against SARS-CoV-2 in the Elderly in the Czech Republic: Hana Tomaskova
  10. 510
    “…About 7.3% and 98% of the exposed population developed IgM and IgG after 3 months of exposure, respectively. The AstraZeneca vaccine was the most used, followed by the Jonhson & Johnson and Sputinik. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immune profile of healthcare professionals six months after vaccination or exposure to SARS‐CoV‐2 in Angola
  11. 511
    “…The article presents a case of a 32-year-old male who developed IgA vasculitis (IgAV) and IgA vasculitis nephritis (IgAVN) after receiving the second dose of the AstraZeneca COVID-19 vaccine. IgAVN can be a rare side effect of COVID-19 vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    First Onset of IgA Vasculitis and Nephritis Following COVID-19 Vaccination
  12. 512
    por Quirke, Viviane
    Publicado 2014
    “…This article compares the research and development (R&D) and marketing strategies of the British group Imperial Chemical Industries (ICI, whose Pharmaceutical Division was spun off and merged with the Swedish company Astra to form AstraZeneca) and its French counterpart Rhône-Poulenc (now part of Sanofi-Aventis) in dealing with the American medical market. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeting the American Market for Medicines, ca. 1950s–1970s:: ICI and Rhône-Poulenc Compared
  13. 513
    por Syed, Yahiya Y.
    Publicado 2017
    “…Intravenous durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Durvalumab: First Global Approval
  14. 514
    por Goodman, Simon L.
    Publicado 2018
    “…Now in its 6th year, the biennial meeting is organized by Andrew Chalmers (University of Bath; CiteAb), this year with Carly Dix (Astra Zeneca).  The organizers gathered some 100 members of industry and academia, producers and users, for a day and a half to describe their efforts to ensure that their antibodies have the desired specificity and selectively for well-defined molecular targets. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The 3rd Antibody Validation meeting: Bath UK 20-21 (st) September 2018
  15. 515
    por Lawton, Graham
    Publicado 2020
    “…Doubts have been raised over some aspects of the test of AstraZeneca and the University of Oxford's covid-19 vaccine. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Trial results come under fire
  16. 516
    por Wilson, Clare
    Publicado 2021
    “…The women who developed the Oxford/AstraZeneca vaccine tell Clare Wilson what went on behind the scenes to create a covid-19 vaccine that has saved thousands of lives…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    “We didn't hold back”
  17. 517
    “…A 22-year-old healthy man was admitted for oedema 15 days after the first injection of the COVISHIELD coronavirus disease 2019 (COVID-19) vaccine (Oxford AstraZeneca) vaccine. Nephrotic syndrome was diagnosed and a kidney biopsy showed minimal change disease. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Adult-onset nephrotic syndrome following coronavirus disease vaccination
  18. 518
    por De Stampa, Matthieu
    Publicado 2021
    “…Older people with pre-existing conditions can now get AstraZeneca's Covid-19 vaccine. We will provide detailed information later. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID Vaccine Rollout for Older Adults in France
  19. 519
    “…Here, we report this challenging case of adult-onset Still's disease in a patient who recently received the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca).…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Adult-Onset Still’s Disease After the ChAdOx1 nCoV-19 Vaccine
  20. 520
    “…We present a case of biopsy-proven unilateral reactive axillary lymphadenopathy in a high risk BRCA carrier following administration of the Astra Zeneca vaccine.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Axillary lymphadenopathy in a high-risk breast screening patient following the COVID-19 vaccine: a diagnostic conundrum
Herramientas de búsqueda: RSS